Loading organizations...
FIGUR8 is a US-based medical technology company that develops an FDA-registered wearable platform designed to provide objective biometric data for musculoskeletal health and injury recovery at any point of care. The organization operates as a business-to-business data solution, licensing its bioMotion Assessment Platform to physical therapy clinics, orthopaedics providers, and healthcare payers across 15 states. This biometric sensing technology originally emerged from collaborative research involving the Boston Red Sox, Massachusetts General Hospital, and the MIT Media Lab to improve injury diagnosis and treatment protocols. To date, the enterprise has raised over $40 million in total funding to scale its diagnostic hardware and software systems across the medical sector. The company is guided by a board of directors that includes representation from early investor First Spark Ventures. FIGUR8 was founded in 2016 by Nan-Wei Gong and Tim Ren.
FIGUR8 has raised $42.0M across 3 funding rounds.
FIGUR8 has raised $42.0M in total across 3 funding rounds.
FIGUR8 has raised $42.0M across 3 funding rounds. Most recently, it raised $25.0M Series A in August 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 8, 2023 | $25M Series A | Manish Kothari | DigiTx Partners, Christina Jenkins | Announced |
| Jun 23, 2021 | $12M Series A | — | E14 Fund, P5 Health Ventures, Phoenix Venture Partners | Announced |
| Aug 1, 2019 | $5M Seed | P5 Health Ventures | Greylock, Habib Haddad | Announced |
FIGUR8 is a Boston-based medtech company developing the first FDA-registered platform for objective, at-home musculoskeletal (MSK) diagnostics and rehabilitation using lightweight, on-body sensors and AI-driven software.[1][2][3] The bioMotion Assessment Platform (bMAP) serves clinicians, physical therapists, payers, and patients by replacing subjective MSK assessments with precise, real-time biomechanics data, enabling telemedicine, personalized recovery plans, faster claims closure, and better outcomes in injury diagnosis, treatment, and tracking.[1][3][7] Growth momentum includes emergence from stealth mode, third-party research validation, partnerships like the American Physical Therapy Association pledge, and expansions into payer solutions and recovery indicators.[3][4][5][7]
FIGUR8 originated from a unique collaboration between MIT scientists, Massachusetts General Hospital Orthopaedics, and the Boston Red Sox to improve MSK injury diagnosis and treatment.[2] Founded by CEO Nan-Wei Gong, Ph.D., an MIT graduate and serial entrepreneur specializing in biomechanical insights, the company leveraged this expertise to create its novel sensor technology.[2] Early traction came from adapting clinic-based diagnostics for home use, achieving FDA registration, and gaining endorsements from sports and medical institutions, marking pivotal moments in shifting MSK care from subjective to data-driven.[1][2][3]
FIGUR8 rides the wave of digital health transformation, particularly in MSK care—a market strained by subjective diagnostics amid rising telemedicine adoption post-pandemic and wearable tech proliferation.[1][2][3] Timing aligns with demands for quantifiable biomarkers in rehab and workers' comp, where imprecise assessments delay recovery and inflate costs; FIGUR8's sensors address this by enabling home-based, clinician-linked monitoring.[3][7] Favorable forces include AI integration for personalized medicine, payer incentives for cost savings, and research momentum (e.g., third-party validations in *Sensors* and *International Biomechanics*).[4] It influences the ecosystem by setting a new data standard, empowering physical therapists and reducing healthcare burdens through objective movement analysis.[2][3][4]
FIGUR8 is poised for expansion by scaling bMAP into enterprise payer contracts, sports performance, and global telehealth, leveraging its FDA status and real-world data for AI-enhanced features like predictive recovery models.[3][7] Trends in wearable biomechanics, value-based care, and MSK prevalence (from aging populations and remote work injuries) will propel growth, potentially amplifying influence via partnerships with insurers and hospitals.[2][3][6] As the pioneer in accessible MSK sensors, expect broader adoption that redefines precision diagnostics, tying back to its mission of objective insights for healthier movement worldwide.[1][2]
FIGUR8 has raised $42.0M in total across 3 funding rounds.
FIGUR8's investors include Manish Kothari, DigiTx Partners, Christina Jenkins, E14 Fund, P5 Health Ventures, Phoenix Venture Partners, Greylock, Habib Haddad.
